PMID- 34605215 OWN - NLM STAT- MEDLINE DCOM- 20220428 LR - 20220428 IS - 2059-2310 (Electronic) IS - 2059-2302 (Linking) VI - 98 IP - 6 DP - 2021 Dec TI - Immunohistochemical detection of "ex novo" HLA-DR in tumor cells determines clinical outcome in laryngeal cancer patients. PG - 517-524 LID - 10.1111/tan.14441 [doi] AB - There are controversial results about the role of "ex novo" HLA-DR expression by tumor cells and its correlation with the oncological outcomes. Unfortunately, little is known about HLA-DR expression in laryngeal cancer tumor cells. The main purpose of this retrospective study is to strengthen the usefulness of studying "ex novo" HLA-DR expression on tumor cells from primary laryngeal squamous cell carcinoma (LSCC) patients and investigate its correlation with clinical outcome. We analyzed HLA-DR expression by immunohistochemical analysis in 56 patients with LSCC. The "ex novo" HLA-DR expression on laryngeal cancer tumor cells, assessing non-neoplastic LSCC - adjacent tissue, and the association of HLA-DR expression (HLA-DR+) with clinical outcomes were investigated. HLA-DR+ tumor cells were detected in 18/56 LSCC patients (32.1%). All specimens of non-neoplastic laryngeal carcinoma-adjacent tissue resulted HLA-DR negative (HLA-DR-). A statistically significant association was observed between HLA-DR + and well differentiated tumors (G1) (p<0.001). The Kaplan-Meier method showed how HLA-DR+ is significantly associated with both a better disease specific survival (HLA-DR+=100% vs. HLA-DR-=77.4%; p=0.047) and a better relapse free survival (HLA-DR+=100% vs. HLA-DR-=72.3%; p=0.021). Cox regression univariate analysis for death of disease confirmed a higher HR for HLA-DR absence on the surface of epithelial tumor cell [HR:37.489; 95% CI:0.750-18730.776; p=0.253] and for high-grade (G3) tumors [HR:18.601; 95% CI:3.613-95.764; p<0.0001]. Our results confirm that MHC class II HLA-DR expression is activated in a sub-set of LSCC patients. Evaluation of HLA-DR expression in LSCC could be useful for prognosis and future approaches towards personalized therapy. CI - (c) 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Prampolini, Chiara AU - Prampolini C AD - Department of Head-Neck and Sensory Organs, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Almadori, Giovanni AU - Almadori G AD - Department of Head-Neck and Sensory Organs, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Bonvissuto, Davide AU - Bonvissuto D AD - Department of Neurosciences, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Barba, Marta AU - Barba M AD - Department of Life Science and Public Health, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Biobank for Personalized Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Giraldi, Luca AU - Giraldi L AD - Department of Life Science and Public Health, Section of Hygiene and Public Health, Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Boccia, Stefania AU - Boccia S AD - Department of Life Science and Public Health, Section of Hygiene and Public Health, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Woman and Child Health and Public Health, Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Paludetti, Gaetano AU - Paludetti G AD - Department of Head-Neck and Sensory Organs, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Galli, Jacopo AU - Galli J AD - Department of Head-Neck and Sensory Organs, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Parolini, Ornella AU - Parolini O AD - Department of Life Science and Public Health, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Biobank for Personalized Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. FAU - Settimi, Stefano AU - Settimi S AUID- ORCID: 0000-0003-0104-1501 AD - Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Cadoni, Gabriella AU - Cadoni G AD - Department of Head-Neck and Sensory Organs, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Department of Aging, Neurologic, Orthopedic and Head-Neck Sciences, Otorhinolaryngology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. LA - eng PT - Journal Article DEP - 20211012 PL - England TA - HLA JT - HLA JID - 101675570 RN - 0 (HLA-DR Antigens) SB - IM MH - Alleles MH - *Carcinoma, Squamous Cell/metabolism MH - HLA-DR Antigens/genetics MH - Humans MH - *Laryngeal Neoplasms/genetics/pathology MH - Neoplasm Recurrence, Local MH - Retrospective Studies OTO - NOTNLM OT - HLA-DR OT - MHC II OT - immunohistochemistry OT - laryngeal squamous cell carcinoma OT - personalized medicine OT - tumor immunology EDAT- 2021/10/05 06:00 MHDA- 2022/04/29 06:00 CRDT- 2021/10/04 06:37 PHST- 2021/09/27 00:00 [revised] PHST- 2021/06/20 00:00 [received] PHST- 2021/09/30 00:00 [accepted] PHST- 2021/10/05 06:00 [pubmed] PHST- 2022/04/29 06:00 [medline] PHST- 2021/10/04 06:37 [entrez] AID - 10.1111/tan.14441 [doi] PST - ppublish SO - HLA. 2021 Dec;98(6):517-524. doi: 10.1111/tan.14441. Epub 2021 Oct 12.